Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1245/s10434-023-14657-z | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Gaps in care across the cancer screening continuum for cervical, colorectal and lung cancer.
J Natl Cancer Inst
September 2025
Public Health Sciences Division, Fred Hutchinson Cancer Center, Seattle, WA, USA.
Background: While screening for cervical, colorectal, and lung cancers reduce cancer-specific mortality, the full benefits of screening are only realized when coupled with timely care across the subsequent "screening continuum" steps, including surveillance (results warranting frequent monitoring), diagnostic evaluation (results that require additional testing), and treatment (detected cancers). Our goal was to describe the proportion of individuals receiving timely cervical, colorectal, and lung cancer care at each step in the screening continuum.
Methods: This retrospective cohort study used data from the 10 health care settings that participate in the Population-based Research to Optimize the Screening Process (PROSPR II) consortium and included individuals who were eligible for a step along the cancer screening continuum in 2018.
Advancing breast cancer and lung cancer screening: Expert perspectives to advance programmes in Singapore.
Ann Acad Med Singap
August 2025
Division of Medical Oncology, National Cancer Centre Singapore, Singapore.
Introduction: The high prevalence and mortality rates of breast cancer and lung cancer in Singapore necessitate robust screening programmes to enable early detection and intervention for improved patient outcomes, yet 2024 uptake and coverage remain suboptimal. This narrative review synthesises expert perspectives from a recent roundtable discussion and proposes strategies to advance breast cancer and lung cancer screening programmes.
Method: A 2024 roundtable convened clinical practitioners, health policymakers, researchers and patient advocates discussed current challenges and opportunities for improving cancer screening in Singapore.
Integrating substance use services into HIV care: an underused implementation science opportunity.
Curr Opin HIV AIDS
September 2025
New York State Psychiatric Institute, New York, New York.
Purpose Of Review: Substance use disorders (SUDs) are common among people with HIV (PWH) and have been linked to sub-optimal HIV care outcomes. Integration of substance use services into HIV care is an implementation strategy with potential to increase uptake of substance use services and improve HIV care outcomes. This review synthesizes recent U.
View Article and Find Full Text PDFEngineered charge adaptive nanoplatform overcomes the drug penetration barriers to potentiate the efficacy of chemotherapy.
Mater Today Bio
October 2025
School of Pharmacy, Henan Medical University, Xinxiang, Henan, China.
Breast cancer continues to present a major clinical hurdle, largely attributable to its aggressive metastatic behavior and the suboptimal efficacy of standard chemotherapeutic regimens. Cisplatin (CDDP) is a representative platinum drug in the treatment of breast cancer, however, its therapeutic application is often constrained by systemic toxicity and the frequent onset of chemoresistance. Here, we introduce a novel charge-adaptive nanoprodrug system, referred to as PP@, engineered to respond to tumor-specific conditions.
View Article and Find Full Text PDFHigh risk factors, molecular features and clinical management for radioactive iodine-refractory differentiated thyroid carcinoma.
Front Oncol
August 2025
Department of Pathology, Institute of Clinical Pathology, Frontiers Science Center for Disease-related Molecular Network, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
Despite the generally favorable prognosis of differentiated thyroid carcinoma (DTC) following surgery and radioactive iodine (RAI) therapy, approximately 10% of cases eventually develop resistance to RAI. This condition, known as radioiodine-refractory differentiated thyroid carcinoma (RAIR-DTC), is associated with a poor prognosis, with a 10-year survival rate of only 10% from the time of metastasis detection. The limited availability of safe and effective alternative treatments poses a significant challenge to clinical management.
View Article and Find Full Text PDF